Arie Regev

7PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Biomolecular modelling and designMolecular targetsLiquid biopsiesToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 04, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Anna Fettiplace, Arie Regev, Alexandre Kiazand

|Feb 25, 2025
Assessment of liver injury potential of investigational medicines in drug development.

Naga Chalasani, Paul H Hayashi, Debra Luffer-Atlas

|Sep 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.

Anna Fettiplace, John Marcinak, Michael Merz

|Oct 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.

Melissa Palmer, David E Kleiner, Zachary Goodman

|Nov 26, 2019
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.

Melissa Palmer, Arie Regev, Keith Lindor

|Feb 15, 2019
Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.

Lauren Pavlik, Arie Regev, Paul A Ardayfio

Pageof 2

Frequent Collaborators

4 joint publications

Melissa Palmer

2 joint publications

Arun J Sanyal

2 joint publications

Naga Chalasani

2 joint publications

Anna Fettiplace